Medical device mergers and acquisitions continued at a steady pace throughout the first half of 2026. The year started off with two large deals: Boston Scientific announced plans to buy Penumbra for $14.5 billion and Abbott closed its $21 billion purchase of cancer test firm Exact Sciences.

Boston Scientific closed another deal last month, paying $1.5 billion for a stake in MiRus to take another shot at the market for transcatheter valve replacement systems. In May, Medtronic announced its third major acquisition so far this year, agreeing to buy SPR Therapeutics, which makes a peripheral nerve stimulation device to treat chronic pain, for about $650 million.

Several medtech firms have also announced major divestitures in the past year. BD sold its biosciences and diagnostics businesses to Waters and Medtronic completed its spinoff of diabetes tech business MiniMed. Johnson & Johnson has also shared plans to divest its orthopedics segment.

Here are the top M&A deals so far this year: